Optimism about prospects for the new diet drug rimonabant (Acomplia) surged on the news that manufacturer Sanofi-Aventis plans to present data from two years of clinical trials, rather than one-year data, at the annual scientific meeting of the American Heart Association on November 9th in New Orleans.
One-year results from clinical trials published earlier this year showed that many patients who stayed on rimonabant for a year lost more than 10 percent of their body Acomplia (rimonabant) weight, while the drug also significantly increased levels of “good” HDL cholesterol.
While further results had been expected to be presented at the American Heart Association meeting, analysts viewed news that Sanofi-Aventis would be presenting two-year data as a sign that rimonabant is continuing to produce encouraging results in the trials underway Acomplia (rimonabant) .
“ They have raced and managed to get the two-year data out and it is being presented at a late-breaking session, so the implication from that is it is positive,” said Commerzbank analyst Marc Booty Acomplia (rimonabant) .
Acomplia (rimonabant) In addition to further data on effectiveness, researchers will also be scrutinizing information on side effects from the longer use of rimonabant. Adverse side effects ultimately have dashed high hopes once held for several earlier diet drugs.
Метки:
clinical,
diet drug,
drug,
results,
side effects,
weight,
Zimulti,
Новости
Посмотрите также
- Zimulti Acomplia News — Oct. 2007 — News About Rimonabant
Diet Drug Taranabant Yields Encouraging Results With ‘Generally Mild’ Side-Effects Taranabant, which a year from now may have surged past (Acomplia) rimonabant as the world’s most eagerly awaited diet drug, made a low-key debut Oct. 24th when researchers reported that participants in a clinical trial achieved encouraging weight loss with [...]
- Sanofi-Aventis Seeks to Shut Down News Coverage by the Acomplia Report
Sanofi-Aventis, developer of the much touted diet drug Acomplia (rimonabant) , has announced its intention to try and shut down the independent Acomplia Report, denying hundreds of thousands of obese and overweight individuals this unbiased source of news about the drug and efforts to bring it to market.
In emails [...]
- Encouraging Acomplia Results Greeted With Mix of Excitement and Caution
Highly encouraging results reported November 9th from the largest trial to date of the new diet drug Acomplia (rimonabant) were greated with a mixture of excitement and caution by the medical community.
Data from a two-year study of rimonabant showed the drug helped obese patients lose four times as much [...]
- Diet Drug Acomplia Sales Disappoint; No Major Improvement Seen Until 2009
Sales of diet drug Acomplia (rimonabant) , available in Europe but not approved in the U.S., have turned into a major disappointment for Sanofi-Aventis, which says it does not expect the situation to significantly improve until new clinical trial results are ready for submission to regulators in 2009.
“ I [...]
- Study: Highly Encouraging Two-Year Trial Results Reported for Acomplia
The new diet drug rimonabant (Acomplia) helped people lose significantly more weight than a placebo in a two-year clinical trial, the largest of the studies of this drug conducted to date, according to researchers.
The study also showed that while most Acomplia (rimonabant) of the weight loss occured [...]
- NICE Recommends Acomplia Be Available Through Britain’s National Health Service
Sanofi-Aventis received a rare piece of good news about diet drug Acomplia (rimonabant) on March 26th when Britain’s National Institute for Health and Clinical Excellence (NICE) recommended that the diet pill be made available to obese and overweight patients through the U.K.’s National Health Service.
NICE assesses the cost-effectiveness of treatments for [...]
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
Еще нет комментариев.
Извините, комментирование на данный момент закрыто.